Collegium to Report Third Quarter 2024 Financial Results on November 7, 2024

COLL 10.24.2024

SERA-AI Powered Highlights
Date of Upcoming Event:2024-11-07
Name of Upcoming Event:Collegium Pharmaceutical Q3 2024 Earnings Call
Full Press ReleaseSEC FilingsOur COLL Tweets

About Gravity Analytica

Recent News

  • 01.08.2025 - Collegium Provides 2025 Financial Guidance and Business Update
  • 12.05.2024 - Piper Sandler 36th Annual Healthcare Conference
  • 11.19.2024 - Jefferies London Healthcare Conference

Recent Filings

  • 01.14.2025 - 4 Statement of changes in beneficial ownership of securities
  • 01.10.2025 - 144 Report of proposed sale of securities
  • 01.08.2025 - 8-K Current report

STOUGHTON, Mass.,Oct. 24, 2024(GLOBE NEWSWIRE) --Collegium Pharmaceutical, Inc.(Nasdaq: COLL), a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions, today announced that it will report third quarter 2024 financial results after the market closes on Thursday, November 7, 2024. Following the release of the financials, the Company will host a live conference call and webcast at 4:30 p.m. ET.

Conference Call InformationTo access the conference call, please dial (877) 407-8037 (U.S.) or (201) 689-8037 (International) and reference the “Collegium Pharmaceutical Q3 2024 Earnings Call.” An audio webcast will be accessible from the Investors section of the Company’s website:www.collegiumpharma.com. The webcast will be available for replay on the Company’s website approximately two hours after the event.

About Collegium Pharmaceutical, Inc.Collegium is a leading, diversified specialty pharmaceutical company committed to improving the lives of people living with serious medical conditions. Collegium’s headquarters are located inStoughton, Massachusetts. For more information, please visit the Company’s website atwww.collegiumpharma.com.

Investor Contact:Danielle JesseDirector, Investor Relationsir@collegiumpharma.com

Media Contact:Marissa SamuelsVice President, Corporate Communicationscommunications@collegiumpharma.com

Primary Logo

Source: Collegium Pharmaceutical, Inc.

Please be aware that the following content has been generated by an AI system and may contain errors, inconsistencies, or outdated information. It is provided as-is without any warranties or guarantees of accuracy. We strongly recommend using this content as a starting point for further research and consultation with relevant experts or authorities. We disclaim any liability for damages or losses resulting from the use or reliance on this content.Please note that this is a beta version of the Gravity Analytica LLC’s AI Service which isstill undergoing final testing before its official release. Theplatform, its software and all content found on it are provided on an“as is” and “as available” basis. Gravity Analytica LLC does not give any warranties,whether express or implied, as to the suitability or usability of thisservice, webpage, or its software or any of its content.Should you encounter any bugs, glitches, lack of functionality orother problems on the website, please let us know immediately so wecan rectify these accordingly. Your help in this regard is greatlyappreciated! You can write to us at this addressteam@gravityanalytica.com